Cancer metastasis: biological mechanisms, therapeutic bottlenecks, and emerging interventions.
- 1Laboratory of Aging Research and Immunology, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- 2Laboratory of Aging Research and Immunology, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [email protected].
- 3Laboratory of Aging Research and Immunology, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [email protected].
Abstract
Metastatic cancer remains a major clinical challenge, which is driven by the continuous adaptation of disseminated tumor cells to diverse tissue environments and therapeutic pressures. Although current treatments, including conventional therapies, small-molecule drugs, antibody-drug conjugates, and immunotherapies, have improved clinical outcomes in selected patients, they rarely achieve durable disease control, largely because each stage of the metastatic cascade presents distinct therapeutic bottlenecks. This review examines these bottlenecks and identifies therapeutic vulnerabilities that can be targeted at each metastatic stage. Cross-stage adaptive programs, encompassing genetic, epigenetic, metabolic, immune, and microenvironmental alterations, are linked to the specific modes of therapeutic failure they drive, thereby connecting underlying mechanisms with their corresponding clinical consequences. Emerging therapeutic strategies are discussed in the context of the metastatic stage, and general design principles for combination regimens are proposed. We also highlight the potential of liquid biopsy-guided dynamic treatment adjustment and advanced preclinical models to inform patient selection, treatment timing, and the design of therapies aimed at overcoming resistance. By integrating metastatic biology, mechanisms of therapeutic failure, and emerging interventions, this review provides a framework for understanding and targeting the bottlenecks that limit durable disease control in metastatic cancer.
Related
- Bone Metastasis and the Immunosuppressive Tumor Microenvironment: Mechanisms and Therapeutic Strategies
- Cuproptosis in glioma: mechanisms, biological roles and therapeutic perspectives
- MiR-532 as a Potential Therapeutic Target and Biomarker: Biological Functions, Molecular Mechanisms, and Clinical Perspectives.
- Magnesium in Skin Aging, Wound Healing, and Some Specific Dermatologic Disorders: A Narrative Review on Biological Mechanisms, Clinical Evidence, and Therapeutic Perspectives
- Hepatoprotective natural polyphenol extracts: molecular mechanisms, stabilization-delivery strategies, and translational bottlenecks for functional food applications
BibTeX
@article{ye2026cancer,
title = {{Cancer metastasis: biological mechanisms, therapeutic bottlenecks, and emerging interventions.}},
author = {Huali Ye and Yuquan Wei and Xuemei He and Xiawei Wei},
journal = {Journal of hematology \& oncology},
year = {2026},
month = oct,
doi = {10.1186/s13045-026-01856-w},
url = {https://europepmc.org/article/MED/42902326},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Cancer metastasis: biological mechanisms, therapeutic bottlenecks, and emerging interventions.
AU - Huali Ye
AU - Yuquan Wei
AU - Xuemei He
AU - Xiawei Wei
PY - 2026
DA - 2026/10/20
JO - Journal of hematology & oncology
DO - 10.1186/s13045-026-01856-w
UR - https://europepmc.org/article/MED/42902326
AB - Metastatic cancer remains a major clinical challenge, which is driven by the continuous adaptation of disseminated tumor cells to diverse tissue environments and therapeutic pressures. Although current treatments, including conventional therapies, small-molecule drugs, antibody-drug conjugates, and immunotherapies, have improved clinical outcomes in selected patients, they rarely achieve durable disease control, largely because each stage of the metastatic cascade presents distinct therapeutic bottlenecks. This review examines these bottlenecks and identifies therapeutic vulnerabilities that can be targeted at each metastatic stage. Cross-stage adaptive programs, encompassing genetic, epigenetic, metabolic, immune, and microenvironmental alterations, are linked to the specific modes of therapeutic failure they drive, thereby connecting underlying mechanisms with their corresponding clinical consequences. Emerging therapeutic strategies are discussed in the context of the metastatic stage, and general design principles for combination regimens are proposed. We also highlight the potential of liquid biopsy-guided dynamic treatment adjustment and advanced preclinical models to inform patient selection, treatment timing, and the design of therapies aimed at overcoming resistance. By integrating metastatic biology, mechanisms of therapeutic failure, and emerging interventions, this review provides a framework for understanding and targeting the bottlenecks that limit durable disease control in metastatic cancer.
SN - 1756-8722
ER -